A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders
NCT06680037
This study is recruiting at 8 US sites in 6 states, according to its ClinicalTrials.gov record last updated .
Summary
The main objective of the study is to determine the recommended phase 2 dose (RP2D) of Azercabtagene zapreleucel (azer-cel).
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- B-cell Mediated Autoimmune Disorders
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- TG Therapeutics, Inc.
- Last updated on ClinicalTrials.gov
- September 9, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- TG Therapeutics Investigational Trial Site · La Jolla, CA
Michigan · 1
- TG Therapeutics Investigational Trial Site · Ann Arbor, MI
Nebraska · 1
- TG Therapeutics Investigational Trial Site · Omaha, NE
New York · 2
- TG Therapeutics Investigational Trial Site · New York, NY
- TG Therapeutics Investigational Trial Site · Rochester, NY
Ohio · 2
- TG Therapeutics Investigational Trial Site · Cleveland, OH
- TG Therapeutics Investigational Trial Site · Columbus, OH
Wisconsin · 1
- TG Therapeutics Investigational Trial Site · Milwaukee, WI
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.